

Mediq Regulations 2007 on the holding of
and transactions in shares and certain other
financial instruments

CONTENTS

	<u>Page</u>
Recitals	5
<u>Chapter I</u>	<u>Introduction</u>
Section 1	Compulsory permission for transactions in Mediq Financial Instruments 5
Section 2	Definitions 6
Section 3	Scope 6
Section 4	Statutory prohibitions and notification obligations 6
<u>Chapter II</u>	<u>General prohibitions applicable to all Mediq Managing Directors, Mediq Supervisory Board Members, Mediq Executives and Designated Mediq Employees</u>
Section 5	Prohibitions against executing transactions with regard to Mediq Financial Instruments 6
Section 6	Prohibitions against executing transactions with regard to Affiliated Financial Instruments 7
Section 7	Prohibitions against executing transactions with regard to Other Financial Instruments 7
Section 8	Prohibition against disclosure; prohibition against making recommendations 8
<u>Chapter III</u>	<u>Notification obligations applicable to all Mediq Managing Directors, Mediq Supervisory Board Members and Mediq Executives</u>
Section 9	Notification obligations by reason of the Wft 9
<u>Chapter IV</u>	<u>Notification obligations applicable to all Mediq Managing Directors and Mediq Supervisory Board Members</u>
Section 10	Notification obligations by reason of the Wft 10
<u>Chapter V</u>	<u>Specific provisions with regard to Mediq Managing Directors</u>
Section 11	Freedom of investment; long-term investments in Mediq Financial Instruments 10
Section 12	Notification obligations by reason of the Wft 10
<u>Chapter VI</u>	<u>Specific provisions with regard to Mediq Supervisory Board Members</u>
Section 13	Freedom of investment; long-term investments in Mediq Financial Instruments 11
Section 14	Notification obligations by reason of the Wft 11
<u>Chapter VII</u>	<u>Specific provisions with regard to Mediq Executives</u>
Section 15	Notification obligations by reason of the Wft 11

Continuation of contents		<u>Page</u>
<u>Chapter VIII</u>	<u>Specific provisions with regard to Designated Mediq Employees</u>	
Section 16	Notification obligations by reason of the Wft	11
<u>Chapter IX</u>	<u>Other Mediq Employees</u>	
Section 17	Prohibition against executing Transactions, Disclosure and Making Recommendations	11
Section 18	Notification obligations	11
<u>Chapter X</u>	<u>Affiliated Persons</u>	
Section 19	Notification obligation	12
<u>Chapter XI</u>	<u>Other provisions</u>	
XI.1	Central Officer	
Section 20	Appointment and dismissal	13
Section 21	Contact details	13
Section 22	Duties and powers	13
Section 23	Advice; exemption	13
Section 24	Annual reporting	13
XI.2	Register	
Section 25	Contents	14
Section 26	Responsibility; objectives	14
Section 27	Provisions to third parties	14
Section 28	Custody; custody period	14
Section 29	Inspection	14
Section 30	Adjustment of data	15
Section 31	Security	15
XI.3	Forms	
Section 32	Forms	15
XI.4	Designations and notification	
Section 33	Designated Mediq Employees	15
Section 34	Closed Periods	15
Section 35	Affiliated Issuing Institutions	16
Section 36	Notification of prohibitions and sanctions	16
XI.5	Final provisions	
Section 37	Sanctions	16

Section 38	Cases not provided for by the Mediq Regulations	16
Further contents		<u>Page</u>
Section 39	Entry into force	16
Section 40	Amendments	16
Section 41	Applicable law	16
Appendix		
Definitions		17 - 20

On 9 November 2007, the Management Board of Mediq NV, with its registered office in Utrecht, laid down the following rules with regard to the holding of and transactions in shares and specific other financial instruments concerning the Mediq NV and affiliated issuing institutions:

Recitals

- I. The Mediq Regulations were adopted in compliance with Section 5:65 of the Wft;
- II. Among other things, the Mediq Regulations aim to promote trading by Mediq Employees with regard to the Financial Instruments that they hold and in connection with the Execution of Transactions in accordance with the law, including the Wft, as well as in accordance with the codes applicable to the Company, including the Dutch Corporate Governance Code, and to limit the risk that the good reputation of the Company and the integrity of its business is harmed as a result of undesirable transactions in Financial Instruments.

Chapter I Introduction

Section 1 Compulsory permission for transactions in Mediq Financial Instruments

- A. Without having received permission thereto from the Central Officer, Executing a Transaction in Mediq Financial Instruments is prohibited for Mediq Managing Directors, Mediq Supervisory Board Members, Mediq Executives and Designated Mediq Employees.
- B. In the event that an Mediq Director, Mediq Supervisory Board Member, Mediq Executive or Designated Mediq Employee intends to Execute a Transaction in Mediq Financial Instruments and has no knowledge of Inside Information and there is no Closed Period, the following will apply to the Mediq Director, Mediq Supervisory Board Member, Mediq Executive and Designated Mediq Employee:
 1. The Mediq Director, Mediq Supervisory Board Member, Mediq Executive or Designated Mediq Employee will notify the Central Officer in writing or electronically of the intention to Execute a Transaction in Mediq Financial Instruments;
 2. The Mediq Director, Mediq Supervisory Board Member, Mediq Executive or Designated Mediq Employee will only give instructions to Execute a Transaction in Mediq Financial Instruments after having received notification from the Central Officer in writing or electronically, confirming the receipt of said notification and granting permission for the intended transaction(s).
 3. The Central Officer will notify the Mediq Director, Mediq Supervisory Board Member, Mediq Executive or Designated Mediq Employee in writing or electronically as swiftly as possible of the receipt of said notification and whether permission has been granted.
 4. The Central Officer will only grant its permission after having entered into consultation with regard hereto with one of the members of the Management Board of the Company. In the event that it concerns a member of the Supervisory Board or the Management Board, the Central Officer will also consult the chairperson or the vice chairperson of the Supervisory Board.

Section 2 *Definitions*

In the Mediq Regulations, the terms the first letter of which is capitalized will have the meanings given in the **Appendix** together with the Mediq Regulations.

Section 3 *Scope*

1. The Mediq Regulations contain rule with regard to the holding of and transactions in Mediq Financial Instruments and Affiliated Financial Instruments by Mediq Employees.
2. The Mediq Regulations are applicable to all Mediq Employers, insofar as the Mediq Regulations do not state otherwise. The Mediq Regulations apply to Mediq Employees regardless of the position from which they Execute Transactions and is also applicable in the event that the Mediq Employee concerned Executes a Transaction for the account of a third party or as a representative of a third party.
3. The Mediq Regulations applicable to Mediq Managing Directors are:
Chapters I to V and XI.
4. The Mediq Regulations applicable to Mediq Supervisory Board Members are:
Chapters I to IV, VI and XI.
5. The Mediq Regulations applicable to Mediq Executives are:
Chapters I to III, VII and XI.
6. The Mediq Regulations applicable to Designated Mediq Employees are:
Chapters I, II, VIII and XI.
7. The Mediq Regulations applicable to Other Mediq Employees are:
Chapters I, IX and XI.
8. The Mediq Regulations applicable to Affiliated Persons are:
Chapters I, X and XI.

Section 4 *Statutory prohibitions and Notification obligations*

The provisions of the Mediq Regulations will leave the prohibitions, including the prohibitions with regard to the abuse of the market and the Notification obligations included in the Wft applicable to all, fully intact.

Chapter II General prohibitions applicable to all Mediq Managing Directors, Mediq Supervisory Board Members, Mediq Executives and Designated Mediq Employees

Section 5 *Prohibitions against executing transactions with regard to Mediq Financial Instruments*

1. All Mediq Managing Directors, Mediq Supervisory Board Members, Mediq Executives and Designated Mediq Employees are prohibited from making use of Inside Information door by directly or indirectly Executing Transactions in Mediq Financial Instruments that the Inside Information concerns for their own account or for the account of third parties.
2. All Mediq Managing Directors, Mediq Supervisory Board Members, Mediq Executives and Designated Mediq Employees are prohibited from making use of Inside Information by attempting directly or indirectly to execute Transactions in Mediq Financial Instruments that the Inside Information concerns for their own account or for the account of third parties.
3. All Mediq Managing Directors Mediq Supervisory Board Members, Mediq Executives and Designated Mediq Employees are prohibited from Executing Transactions in Mediq Financial Instruments in a Closed Period, regardless of whether use is thereby made of

- Inside Information by the Mediq Director, Mediq Supervisory Director, Mediq Executive or Designated Mediq Employee.
4. All Mediq Managing Directors, Mediq Supervisory Board Members, Mediq Executives and Designated Mediq Employees are prohibited from Executing Transactions in Mediq Financial Instruments during a period other than a Closed Period in which this is prohibited to the Mediq Director, Mediq Supervisory Director, Mediq Executive or Designated Mediq Employee by the Central Officer on the grounds of paragraph 6.
 5. All Mediq Managing Directors, Mediq Supervisory Board Members, Mediq Executives and Designated Mediq Employees are prohibited from Executing a Transaction in Mediq Financial Instruments and within six months thereafter Executing another Transaction in Mediq Financial Instruments, if the other Transaction is the opposite of the first Transaction or has the effect of undoing or limiting the risk of the first Transaction.
 6. The Central Officer can prohibit Mediq Managing Directors, Mediq Supervisory Board Members, Mediq Executives and Designated Mediq Employees from Executing Transactions in Mediq Financial Instruments in a certain period outside the Closed Period to be determined by the Central Officer.
 7. The prohibition stated in paragraph 1 will not apply to the Execution of Transactions in the discharge of a due and payable obligation existing at the time that the Mediq Managing Director, Mediq Supervisory Director, Mediq Executive or Designated Mediq Employee acquired Inside Information (e.g. an obligation to dispose of or acquire Mediq Financial Instruments by reason of an agreement concluded before the Inside Information was acquired).
 8. The prohibition stated in paragraph 1 is moreover not applicable to:
 - a. The acceptance of Mediq Financial Instruments in connection with a personnel plan, in the event that a durable line of conduct is thereby employed with regard to the conditions and the periodicity of the regulation;
 - b. The acquisition of shares or depositary receipts for shares in the capital of the Company by means of dividend distribution, other than in the form of optional dividend.
 9. Paragraphs 7 and 8 will apply by analogy to the prohibitions included in the paragraphs 3 up to and including 5.
 10. The prohibitions stipulated in paragraphs 1 up to and including 5 and any possible exceptions thereto will continue to apply for another six months after an Mediq Director, Mediq Supervisory Director, Mediq Executive or Designated Mediq Employee has lost his position.

Section 6 *Prohibitions against executing transactions with regard to Affiliated Financial Instruments*

That stipulated in Section 4 will apply by analogy to Affiliated Financial Instruments.

Section 7 *Prohibitions against executing transactions with regard to Other Financial Instruments*

1. All Mediq Executives and Designated Mediq Employees are prohibited from Executing Transactions in Other Financial Instruments, if they have received such a designation from the Management Board of the Company in accordance with paragraph 3 and the Mediq Executives and Designated Mediq Employees concerned have been notified of this designation, regardless of whether Inside Information concerning the relevant Other Financial Instruments is thereby used by the Mediq Executives or Designated Mediq Employee.

2. All Mediq Executives and Designated Mediq Employee are prohibited from Executing Transactions in Other Financial Instruments, if the Central Officer has determined such in accordance with paragraph 4 and the Mediq Executives or Designated Mediq Employees concerned have been informed hereof, regardless of whether Inside Information concerning the relevant Other Financial Instruments is thereby used by the Mediq Executives or Designated Mediq Employees.
3. The Management Board can determine that an Mediq Executive or Designated Mediq Employee is not to Execute Transactions in certain Other Financial Instruments determined by the Management Board, if it is plausible that by reason of his or her position in the Company, the Mediq Executives or Designated Mediq Employee can make a better assessment of the course of affairs within the issuing institution of the Other Financial Instruments than possible on the grounds of public information, for example regarding certain competitors of the Company.
4. The Central Officer can determine that in a period to be determined by the Central Officer, an Mediq Executive or Designated Mediq Employee must not Execute any Transactions in Other Financial Instruments if the Central Officer is of the opinion that the Mediq Executive or Designated Mediq Employee concerned have or can have Inside Information concerning Other Financial Instruments or if the Central Officer is of the opinion that the Mediq Executive or Designated Mediq Employee concerned can give the impression that he or she would be violating the law if he or she were to Execute a Transaction in those Other Financial Instruments.
5. The prohibitions included in paragraphs 1 and 2 are not applicable to the Execution of Transactions in the discharge of a due and payable obligation which already existed at the time of (e.g. an obligation to dispose of or acquire Other Financial Instruments by reason of an earlier concluded agreement) the designation or prohibition referred to in the paragraphs 3 and 4.
6. The prohibitions included in paragraphs 1 and 2 are moreover not applicable to:
 - a. The acquisition of shares or depositary receipts for shares in the capital of the company issued by the Other Financial Instruments by means of dividend distribution, other than in the form of an optional dividend.
 - b. other transactions excluded by or pursuant to the law.
7. The prohibitions included in the paragraphs 1 and 2 will continue to apply for another six months after an Mediq Executive or Designated Mediq Employee has lost his position.
8. For the Mediq Managing Directors and Mediq Supervisory Board Members, this subject has been regulated in the Regulations concerning the holding of and transactions in Other securities.

Section 8 *Prohibition against disclosure: prohibition against making recommendations*

1. All Mediq Managing Directors, Mediq Supervisory Board Members, Mediq Executives and Designated Mediq Employees are prohibited from notifying third parties of Inside Information, unless this takes place in connection with the ordinary performance of their duties and the person receiving the Inside Information has a duty to confidentiality, regardless of whether this is based on legislation or regulations, provisions in the articles of association or an agreement.
2. All Mediq Managing Directors, Mediq Supervisory Board Members, Mediq Executives and Designated Mediq Employees are prohibited from recommending that a third party Execute

Transactions in Financial Instruments or inciting a third party to Execute Transactions in Financial Instruments that this Inside Information concerns.

Chapter III Notification obligations applicable to all Mediq Managing Directors, Mediq Supervisory Board Members and Mediq Executives

Section 9 Notification obligations by reason of the Wft

1. All Mediq Managing Directors, Mediq Supervisory Board Members or Mediq Executives will notify the AFM on the fifth working day after the Transaction date at the latest of Transactions Executed for their own account in shares in the capital of the Company or Financial Instruments the value of which was determined among other things by the value of these shares.
2. The notification obligation laid down in paragraph 1 does not apply to Transactions Executed on the grounds of a written mandate or realized by a financial company permitted under the Wft to manage private portfolios, if the mandate determines that the Mediq Director, the Mediq Supervisory Director or the Mediq Executives as principal cannot exercise any influence on Transactions Executed or realized by the financial company as an authorized representative. All Mediq Managing Directors, Mediq Supervisory Board Members and Mediq Executives are obliged to give the Central Officer a copy of the mandate as referred to in the last sentence and to notify the Central Officer in writing of all amendments made to this mandate (= discretionary management agreement).
3. The notification referred to in paragraph 1 can be deferred up to the time that added to the Transactions Executed for his or her account in the relevant calendar year with the Persons Affiliated with him or her, the Transactions Executed for his or her account in the relevant calendar year by the Mediq Director, the Mediq Supervisory Director or the Mediq Executive have reached a total amount of EUR 5,000 or more;
4. If the Mediq Director or the Mediq Supervisory Director has made notification in accordance with the applicable sections of the Wft, he or she will be deemed to have complied with the notification obligation laid down in paragraph 1.
5. An Mediq Director, an Mediq Supervisory Director or an Mediq Executive can ask the Central Officer to make the notification to the AFM referred to in this section on his or her behalf. This request must be made in writing each time. The Central Officer must have received the request before 13.00 hours, two working days before the last working day on which the notification must be made to the AFM at the latest. All information that the AFM must be notified of must be provided together with the request. The Mediq Director, the Mediq Supervisory Director or the Mediq Executive will remain responsible for the notification made to the AFM themselves at all times.
6. All Mediq Managing Directors, Mediq Supervisory Board Members or Mediq Executives will notify the Central Officer immediately of each Transaction that they have Executed in Mediq Financial Instruments and Affiliated Financial Instruments.
7. All Mediq Managing Directors, Mediq Supervisory Board Members or Mediq Executives are obliged to notify the Persons Affiliated with him or her of their notification obligations as laid down in Section 20 of these Mediq Regulations.

Chapter IV Notification obligations applicable to all Mediq Managing Directors and Mediq Supervisory Board Members

Section 10 Notification obligations by reason of the Wft

1. Within two weeks of his or her appointment as Mediq Director or Mediq Supervisory Director, all Mediq Managing Directors or Mediq Supervisory Board Members will notify the AFM of the number of Shares and Votes in the Company and the Affiliated Issuing institutions at their disposal.
2. In the event that another public limited company according to Dutch law becomes an Affiliated Issuing Institution, all Mediq Managing Directors or Mediq Supervisory Board Members will notify the AFM immediately of the number of Shares and Votes in the Affiliated Issuing Institution at their disposal. The obligation on the grounds of the last sentence will have been complied with if notification is made hereof on the grounds of other applicable provisions of the Wft.
3. All Mediq Managing Directors or Mediq Supervisory Board Members will notify the AFM immediately of all amendments made to the number of Shares and Votes in the Company and the Affiliated Issuing institutions at their disposal. The obligation on the grounds of the last sentence will have been complied with if notification is made hereof on the grounds of other applicable provisions of the Wft.
4. An Mediq Director or an Mediq Supervisory Director can request that the Central Officer make the notification to the AFM referred to in this section on his or her behalf. The request must be submitted in writing each time. The Central Officer must have received the request before 13.00 hours, two working days prior to the last working day on which the notification can be made to the AFM at the latest. All information that must be reported to the AFM must be provided together with the request. The Mediq Director or Mediq Supervisory Director will remain responsible for the notification to the AFM at all times.

Chapter V Specific Provisions with regard to Mediq Managing Directors

Section 11 Freedom of Investment; long-term investment in Mediq Financial Instruments

1. Unless the provisions in and under the Mediq Regulations do not state otherwise, Mediq Managing Directors are free to invest in Financial Instruments.
2. Any holding of Mediq Financial Instruments by an Mediq Managing Director will be for long-term investment purposes at all times.

Section 12 Notification obligations by reason of the Wft

All Mediq Managing Directors are subject to the provisions of the Wft applicable to all with regard to their holding of Shares and Votes and amendments thereto, including Shares and Votes in the Company and Affiliated Issuing institutions.

Chapter VI Specific provisions with regard to Mediq Supervisory Board Members

Section 13 Freedom of investment; long-term investments in Mediq Financial Instruments

1. Unless the provisions in and under the Mediq Regulations do not state otherwise, Mediq Supervisory Board Members are free to invest in Financial Instruments.
2. Any holding of Mediq Financial Instruments by an Mediq Supervisory Director will be for long-term investment purposes at all times.

Section 14 Notification obligations by reason of the Wft

All Mediq Supervisory Board Members are subject to the provisions of the Wft applicable to all with regard to their holding of Shares and Votes and amendments thereto, including Shares and Votes in the Company and Affiliated Issuing institutions.

Chapter VII Specific provisions with regard to Mediq Executives

Section 15 Notification obligations by reason of the Wft

All Mediq Executives are subject to the provisions of the Wft applicable to all with regard to their holding of Shares and Votes and amendments thereto, including Shares and Votes in the Company and Affiliated Issuing Institutions.

Chapter VIII Specific provisions with regard to Designated Mediq Employees

Section 16 Notification obligations by reason of the Wft

All Designated Mediq Employees are subject to the provisions of the Wft applicable to all with regard to their holding of Shares and Votes and amendments thereto, including Shares and Votes in the Company and Affiliated Issuing institutions.

Chapter IX Other Mediq Employees

Section 17 Prohibitions against Executing transactions, disclosure and making recommendations

1. All Other Mediq Employees who know or must within reason suspect that they have Inside Information at their disposal are prohibited from making use of that Inside Information by Executing a Transaction in Financial Instruments, including Mediq Financial Instruments and Affiliated Financial Instruments which the Inside Information concerns.
2. All Other Mediq Employees who know or must within reason suspect that they have Inside Information at their disposal are prohibited from making use of that Inside Information by attempting to Execute a Transaction in Financial Instruments, including Mediq Financial Instruments and Affiliated Financial Instruments which the Inside Information concerns.
3. All Other Mediq Employees who know or must within reason suspect that they have Inside Information at their disposal are prohibited from passing on that Inside Information to a third party, other than in the normal performance of their duties, professions or the normal exercising of their positions and provided the person receiving the Inside Information has a duty of confidentiality, regardless of whether this is based on legislation or regulations, provisions in the articles of association or an agreement.
4. All Other Mediq Employees who know or must within reason suspect that they have Inside Information at their disposal are prohibited from recommending to a third party that he or

she Execute or from inciting a third party to Execute Transactions in Financial Instruments, including Mediq Financial Instruments and Affiliated Financial Instruments which the inside Information concerns.

5. The prohibition stated in paragraph 1 is not applicable to the Execution of Transactions in the discharge of a due and payable obligation that already existed at the time at which (e.g. in connection with an obligation to dispose of or acquire Financial Instruments by reason of an agreement concluded before) the Other Mediq Employee acquired Inside Information.
6. The prohibition stated in paragraph 1 is moreover not applicable to:
 - a. the acceptance of Financial Instruments in connection with a personnel plan, if a durable line of conduct is thereby employed with regard to the conditions and the periodicity of the regulations;
 - b. the acquisition of shares or depositary receipts for shares in the capital of the Company by means of dividend distribution, other than in the form of optional dividend.

Section 18 Notification obligations by reason of the Wft

All Other Mediq Employees are subject to the provisions of the Wft applicable to all with regard to their holding of Shares and Votes and amendments thereto, including Shares and Votes in the Company and Affiliated Issuing institutions.

Chapter X Affiliated Persons

Section 19 Notification obligation

1. All Affiliated Persons will notify the AFM for their own account on the fifth working day after the Transaction date at the latest of Transactions Executed in shares in the capital of the Company or Financial Instruments the value of which is, among other things, determined by the value of these shares.
2. The notification obligation laid down in paragraph 1 is not applicable to a Transaction Executed on the grounds of a written mandate ("*vrije-hand-rekening*") by a financial company permitted pursuant to the Wft to manage private portfolios which determine that a Affiliated Person as a principal cannot exercise any influence on Transactions Executed by the asset manager as authorized representative.
3. The notification referred to in paragraph 1 can be deferred until the time at which added to the Transactions Executed for his or her own account in the relevant calendar year with the Mediq Managing Director, Mediq Supervisory Director or Mediq Executive affiliated with him or her the Affiliated Person has Executed Transactions for his or her own account in the relevant calendar year reaching a total sum of EUR 5,000 or more.
4. Affiliated Persons are obliged to make the notification to AFM referred to in paragraph 1 themselves, unless they have submitted a request to the Central Officer before 13.00 hours, two working days prior to the last working day on which the notification must be made to the AFM at the latest, requesting that the Central Officer made the notification referred to in paragraph 1 on their behalf. The request must be made in writing and contain all information that must be communicated to the AFM. The Affiliated Person will remain responsible for notifying the AFM him or herself at all times.
5. If the Affiliated Person states to have made notification in accordance with the applicable sections of the Wft, he or she will be deemed to have complied with the notification obligation laid down in paragraph 1.

Chapter XI Other Provisions

XI.1 Central Officer

Section 20 Appointment and Dismissal

The Management Board of the Company will designate a Central Officer . The Management Board of the company can withdraw the designation of the Central Officer at any time. The Chairperson of the Management Board of the Company will act as Central Officer for the Mediq Employee designated as Central Officer .

Section 21 Contact details

The Central Officer is: F.J.J. Scheefhals LL.M., Hertogswetering 159, 3543 AS in Utrecht, tel.: 030 282 12 11, fax: 030 282 12 77, e-mail: frans.scheefhals@Mediq.com and in the event of his/her absence, Ms C.H. van Buttingha Wichers, Hertogswetering 159, 3543 AS in Utrecht, tel.: 030 282 16 09, fax: 030 282 16 90, e-mail: Catrien.v.buttingha@Mediq.com

Section 22 Tasks and powers

The Central Officer will have the tasks and powers assigned to the Central Officer in the Mediq Regulations. The Management Board of the Company can assign the Central Officer supplementary tasks and powers.

Section 23 Advice; exemption

1. At the request of an Mediq Employee, the Central Officer can issue advice with regard to the question of whether a prohibition or obligation incorporated into the Mediq Regulations are applicable to him or her. If an Mediq Employee has any doubts as to the question of whether a prohibition or obligation incorporated into the Mediq Regulations is applicable to him or her, it is recommended that he or she contact the Central Officer to request advice on the matter.
2. In the event of exceptional circumstances and in consultation with a member of the Management Board, or in the event that a member of the Management Board is concerned, in consultation with the chairperson of the supervisory board, or in the event that this chairperson is concerned with the vice chairperson of the Supervisory Board, the Central Officer can grant exemption from the prohibitions and obligations stipulated in the Mediq Regulations.

Section 24 Annual reporting

The Central Officer will report to the chairperson of the Management Board of the Company, is so required each year at the end of the fiscal year of the Company, on the performance of his or her duties and the exercising of his or her powers.

XI.2 Register

Section 25 Contents

The Company will keep a Register containing the following:

- a. The names of the Mediq Managing Directors, Mediq Supervisory Board Members, Mediq Executives, Designated Mediq Employees and Affiliated Persons, as well as all other persons employed with the Company who may have regular or incidental knowledge of Inside Information;
- b. The reason why the other persons referred to in a. have been included in the Register;
- c. The circumstances in which and the time at which a person no longer has access to Inside Information;
- d. All notification made to the Central Office on the grounds of the Mediq Regulations;
- e. all orders issued to the Central Officer concerning notification to be made as referred to in the Mediq Regulations;
- f. all requests made to the Central Officer to grant exemption and all exemption granted by the Central Officer as referred to in Section 23 paragraph 2;
- g. copies of the property agreements received by the Central Officer on the grounds of Section 9 paragraph 2.

The Register and all movements thereto must be dated.

Section 26 Responsibility: objectives

The Company is responsible for the processing of the Personal Data recorded or to be recorded in the Register. Personal Data will only be processed in accordance with the objectives referred to in Section 1 of the Mediq Regulations.

Section 27 Provisions to third parties

Personal Data from the Register may be provided to the AFM, if this is required with a view to complying with a statutory obligation or a major interest of the Company.

Section 28 Custody; custody period

The Register will be kept by the Central Officer. The Personal Data referred to in Section 25 under a. up to and including c. will be kept for at least five years after having been included in the Register or alternation thereof. The Central Officer will remove other Personal Data from the Register two years after the person concerned no longer works for the company at the latest. In the event that the processing of Personal Data as referred to in Section 27 is required for the settlement of a dispute or concerns property rights and obligations of the Company, the data concerned will not be removed. In the event that the processing of the Personal Data is required for the settlement of a dispute, the Central Officer will remove it as soon as it ceases to be relevant in connection with the dispute. In the event that the Personal Data concerns the property rights and obligations of the Company, the Central Officer will remove it seven years after the date on which it was recorded.

Section 29 Inspection

Any Mediq Employee with regard to whom the Register contains Personal Data will have the right to make a request to inspect this data. He or she may apply to the Central Officer to this end. In the event that with regard to the Mediq Employee making the request Personal Data is processed, the Central Officer will provide him or her with a full written overview thereof within four weeks.

Section 30 Adjustment of data

Mediq Employees whose Personal Data has been included in the Register are entitled to request the Company to improve, supplement, remove or protect his or her Personal Data included in the Register,

in the event that this information is factually incorrect or irrelevant to the object of inclusion in the Register. Such a request must be made to the Central Officer. The Central Officer will notify the person concerned in writing within four weeks of the receipt of the request as to whether the request has been complied with. In the event of a decision to refuse the request, the reasons for the refusal will be given. If the request is granted, the Central Officer will implement the improvement, addition, removal or protection of the Personal Data concerned as soon as possible. The Central Officer will notify the AFM as swiftly as possible of any improvements, additions, removal or protection of Personal Data insofar that this data had been passed on to the AFM.

The Central Officer will adjust the data included in the Register without delay in the event that:

- a. the reason why a person is included in the Register, changes;
- b. a person must be added to the Register; and
- c. a person included in the Register no longer has access to Inside Information.

Section 31 Security

The Register will be adequately protected. Only the Central Officer, his/her deputy and their secretaries and the chairperson of the Management Board and the Supervisory Board of the Company are entitled to inspect the Register in the event that this is required flowing from their position and for the objectives stated in Section 1 of the Mediq Regulations.

XI.3 Forms

Section 32 Forms

All notifications referred to in the Mediq Regulations must be made by using the (electronic) forms decided on by the AFM. The Central Officer will supply the forms. The questions asked in the forms must be answered fully and accurately.

XI.4 Designation and notification

Section 33 Designated Mediq Employees

The Central Officer will designate Mediq Employees who by reason of the performance of their duties, profession or their position have access to Inside Information as Designated Mediq Employees and will notify them of such a designation in writing.

Section 34 Closed Periods

The Management Board of the Company will announce in good time before the start of each fiscal year which periods in the fiscal year concerned will apply as Closed Periods. Any changes or additions will be made known in the same way in the course of the fiscal year.

Section 35 Affiliated Issuing institutions

The Management Board of the Company will announce which public limited companies according to Dutch law, the (depository receipts for) shares or transferable securities similar to (depository receipts for) shares have been admitted to trading in a regulated market, will be regarded as Affiliated Issuing institutions for the purpose of the Mediq Regulations. This notification will be made immediately following the entry into force of the Mediq Regulations and subsequently in the event of any change to the Affiliated Issuing Institutions.

Section 36 Notification of prohibitions and sanctions

The Company will notify the Mediq Managing Directors, Mediq Supervisory Board Members, Mediq Executives, Designated Mediq Employees and Affiliated Persons, as well as all other persons working at the Company who may regularly or incidentally have cognizance of Inside Information of the prohibitions of Chapter 5.4.2 of the Wft and the sum of the sanctions set in the event of violation thereof.

X1.5 Final provisions

Section 37 Sanctions

The Company and/or the employer retain the right in the event of the violation of one or more provisions of the Mediq Regulations to impose sanctions that she or he may impose on the grounds of the law and/or the (employment) agreement with the person concerned, including the termination of the (employment) agreement with the person concerned, possibly with immediate effect.

Section 38 Cases not provided for by the Mediq Regulations

In all cases which the Mediq Regulations fail to provide for, the Management Board of the Company is authorized to make a decision, with due observation of any applicable legal provisions.

Section 39 Entry into force

1. The Mediq Regulations will enter into effect on 1 December 2007.
2. The Mediq Regulations will replace the Mediq Regulations 2002 concerning inside information as from 1 December 2007.

Section 40 Amendments

Provisions of the Mediq Regulations can be amended and supplemented on the decision of the Management Board of the Company. Amendments and additions thereto will enter into effect as of the time at which they are announced, unless a later date is indicated on their announcement.

Section 41 Applicable law

The Mediq Regulations are subject to Dutch law.

APPENDIX

Definitions

In the Mediq Regulations, the terms summarized below, the first letter of which is capitalized, will have the meaning given below.

Shares	:	<ul style="list-style-type: none">a. Transferable shares as referred to in Section 79 paragraph 1 of Book 2 Dutch Civil Code;b. depositary receipts for shares or other transferable securities comparable with (depositary receipts for) sharesc. other transferable securities, not being options as referred to under d., by which the shares or securities referred to under a. or b. can be acquired;d. options to acquire the shares or securities referred to under a. and b.
Designated Mediq Employee(s)	:	Mediq Employee(s), not being Mediq Executives, who on the basis of the performance of their duties, profession or position have access to Inside Information and who have been designated as such by the Central Officer
AFM	:	Netherlands Authority for the Financial Markets
Central Officer	:	The Official referred to in Section 21 of the Mediq Regulations
Financial Instruments	:	<ul style="list-style-type: none">a. (depositary receipts for) shares; orb. other financial instruments within the meaning of Section 1:1 of the Wft j° Section 5:53 paragraph 3 of the Wft,<ul style="list-style-type: none">(i) which have been admitted to trading in a regulated market in the Netherlands or for which admission to that trading has been applied for. or(ii) which have been admitted to trading in a regulated market in another Member State or for which a request has been made for admission to trading on that market, or(iii) which have been admitted to trading in a market in financial instruments which is established and officially authorized in a state that is not a Member State or for which a request has been made for admission to trading in that market,c. financial instruments, not being financial instruments as referred to in a or b, the value of which is determined among other things by the value of the financial instruments referred to in a of b, ord. financial instruments which have been admitted to trading in a market in financial instruments, not being a regulated market, whose operator has been

		recognized as referred to in Section 5:26 paragraph 1 of the Wft
Affiliated Financial Instruments	:	Financial Instruments issued by or concerning an Affiliated Issuing Institution.
Affiliated Persons	:	<ul style="list-style-type: none"> a. spouses, registered partners or life partners of, or other persons cohabiting in a similar way with an Mediq Director, an Mediq Supervisory Director or an Mediq Executive; b. children of an Mediq Director, an Mediq Supervisory Director or an Mediq Executive, who fall under his or her authority or who are under legal restraint and for whom an Mediq Director, an Mediq Supervisory Director or an Mediq Executive has been appointed as guardian; c. other relatives related by blood or otherwise of an Mediq Director, Mediq Supervisory Director or Mediq Executive who have on the Transaction date shared a joint household with him or her for at least one year; d. legal persons, trusts as referred to in Section 1 under c of the Act on the Supervision of Trust Offices (<i>Wet toezicht trustkantoren</i>) or partnerships (i) the executive responsibility of which is vested in an Mediq Director, Mediq Supervisory Director or an Mediq Executive or with a person as referred to in sections a. up to and including c., (ii) which are controlled by an Mediq Director, Mediq Supervisory Director or an Mediq Executive or a person as referred to in paragraphs a. up to and including c., (iii) which have been created for the benefit of an Mediq Director, Mediq Supervisory Director or an Mediq Executive or a person as referred to in paragraphs a. up to and including c., or (iv) the economic interests of which are essentially equal to those of an Mediq Director, Mediq Supervisory Director or an Mediq Executive or a person as referred to in paragraphs a. up to and including c.
Affiliated Issuing Institution	:	<p>A public limited company according to Dutch law the (depository receipts for) shares of which (or the transferable securities equivalent to depository receipts for shares) have been admitted to trading in a regulated market:</p> <ul style="list-style-type: none"> a. which belongs to the same group as the Company or in which the Company holds a participating interest as referred to in Section 24c Book 2 Dutch Civil Code, and the turnover of which as most recently determined constitutes as least 10% of the consolidated turnover of the Company; or b. which directly or indirectly generates over 25% of the capital of the Company
Closed Period	:	<ul style="list-style-type: none"> a. the period of two months prior to the first publication of the annual figures of the Company; b. the period of 21 days prior to the first publication of the quarterly of semi-annual

figures of the Company

Derivatives on commodities	:	Derivatives on commodities are Financial Instruments the value of which is determined among other things by the value of the raw materials that they concern
Member State	:	A state that is a member of the European Union as well as a state, not being a Member State of the European Union, which is a party to the Agreement on the European Economic Space
Dutch Corporate Governance Code	:	The code of conduct designated in the order in council referred to in Section 391 paragraph 4 Book 2 Dutch Civil Code.
Mediq Managing Director(s)	:	The persons comprising the body according to the articles of association charged with the management of the Company
Mediq Supervisory Director(s)	:	The persons comprising the body according to the sections of association charged with supervising the management of the Company
Mediq Financial Instrument(s)	:	Financial Instruments issued by or concerning the Company
Mediq Executive(s)	:	Mediq Employees, not being Mediq Managing Directors of Mediq Supervisory Board Members, who have an executive position and by reason thereof are authorized to make decision that have consequences for the future business developments prospects of the Company and who can regularly have Inside Information at their disposal
Register	:	The register referred to in Section 25 et seq. of the Mediq Regulations
Votes	:	Votes that can be cast on Shares, including rights pursuant to an agreement to acquire votes.
Transaction date	:	The date on which a Transaction is Executed
Company	:	Mediq N.V., with its registered office in Utrecht
Execution of Transactions	:	Directly or indirectly buying or selling or executing another legal act for one's own account or for the account of a third party for the purpose of the acquisition or alienation of Financial Instruments
Inside Information	:	a. with regard to Financial Instruments, not being Derivatives on Commodities, Inside Information is knowledge of information of a precise nature which has not been made public, relating directly or indirectly to the legal person, company or institution that the Financial Instruments concern or to the trade in these Financial Instruments, which if it were publicly made known would have a significant influence on the price of the Financial Instruments or on related derivative Financial Instruments;

- b. with regard to Derivatives on Commodities, Inside Information is knowledge of information of a precise nature which has not been publicly made known and directly or indirectly concerns one or more of those Derivatives on Commodities, which information investors in those Derivatives on Commodities would expect to be made public in accordance with usual market practices in the regulated markets in which those Derivatives on Commodities are traded. Information which investors would expect to be made public would be information of such a nature that it:
- (i) is routinely made available to investors in those Financial Instruments;
 - (ii) should be made publicly available in line with legal requirements applicable to those regulated market rules or according to the market rules, agreements or accepted practices in that regulated market.

Wft

: Financial Supervision Act